



CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems

Copenhagen, Denmark and Seattle, WA – January 5, 2012 – [CMC Biologics](#), a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.

“CMC Biologics is continually innovating to advance [biopharmaceutical manufacturing](#) to the next level. Our expertise in developing efficient production processes puts our clients’ projects in an optimal position to succeed,” said Mads Laustsen, Chief Scientific Officer of CMC Biologics and Inventor. “This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target.”

Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment. Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration — a significant advantage for the [downstream processing](#).

About CMC Biologics

[CMC Biologics](#) is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company’s fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

Media Inquiries:

Stacie D. Byars | sbyars@cmcbio.com
CMC Biologics Global Marketing
+1 (425) 415.5438 (office)
+1 (206) 660.2588 (mobile)